

Message

---

**From:** Niman, Aaron [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A8893877540D416D880562DD19AB78A4-NIMAN, AARO]  
**Sent:** 8/30/2017 6:58:11 PM  
**To:** Miller, David [Miller.DavidJ@epa.gov]  
**CC:** Woods, Stacy [woods.stacy@epa.gov]; Aldridge, Ashlee [Aldridge.Ashlee@epa.gov]  
**Subject:** Paraquat Literature Review & NTP Systematic Review  
**Attachments:** Paraquat\_PD\_Distiller Tracking\_EXPORT\_071917\_Westat NTP Crosswalk.xlsx

David, Stacy, and Ashlee,

During our TEB meeting today, we briefly discussed that Austin Wray will be leading a systematical literature review of Paraquat <-> Parkinson's that will be conducted by National Toxicology Program (NTP) and include human observational studies.

Given our related review work with Westat, I have reviewed the extent of overlap between NTP's literature review (via contractor ICF) and the EndNote Library compiled by Westat. A summary of this comparison is provided below and my more detailed spreadsheet is attached for your reference.

**Westat Lit. Screening**

- **474** = potential human studies (Paraquat and all outcomes)
- **~44** = studies relevant for Paraquat epidemiology review
- **~19/44** = studied focused on Parkinson's Disease

**NTP/ICF Lit. Screening**

- **22** = relevant human studies for their systematic review
- **19 of these 22 studies** were also identified in Westat review

## Ex. 5 Deliberative Process (DP)

Let me know if you have any questions.

Thanks,

-Aaron

**Aaron Niman**

*Environmental Health Scientist  
LCDR, U.S. Public Health Service*

Health Effects Division | Office of Pesticide Programs  
Office of Chemical Safety and Pollution Prevention  
U.S. Environmental Protection Agency  
Tel: 703.347.8184  
[Niman.Aaron@epa.gov](mailto:Niman.Aaron@epa.gov)

